Federal and State False Claims Act Overview

This document is a guide that outlines the implications of the Federal and State False Claims Act (FCA) for health care and life sciences companies. It describes the risks associated with FCA laws, particularly those initiated by private qui tam relators, emphasizing the financial and reputational impacts on organizations. The guide details how FCA investigations can be costly and disruptive, even when they do not lead to verdicts or settlements. It presents the services offered by a legal group specializing in FCA matters, including defense strategies and compliance measures to mitigate litigation risks. The document explains the group’s approach to navigating FCA claims, from initial inquiries to trial, highlighting their expertise in health care law and regulatory compliance. It also discusses the importance of discreet handling of cases to avoid media attention and operational disruptions, while aiming for optimal outcomes in negotiations and litigation.